🔎 Trials Near Me

Home › Carcinoma in Situ › California

Carcinoma in Situ clinical trials in California

5 studies for Carcinoma in Situ are looking for participants at sites in California.

Cities in California

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

  • Michael G Oefelein Clinical Trials ( Site 0138), Bakersfield
  • USC Norris Comprehensive Cancer Center ( Site 0123), Los Angeles
  • Genesis Healthcare-Torrance ( Site 0140), Torrance
  • and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06833073

Project: Every Child for Younger Patients With Cancer

  • Kaiser Permanente Downey Medical Center, Downey
  • City of Hope Comprehensive Cancer Center, Duarte
  • Loma Linda University Medical Center, Loma Linda
  • and 15 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

  • Michael Oefelein Clinical Trials, Bakersfield
  • University of California Irvine Medical Center, Orange
  • Genesis Research LLC, Torrance
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT05951179

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

  • Michael Oefelein Clinical Trials, Bakersfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07480356

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  • University of California - Irvine Medical Center, Irvine
  • UC San Diego Moores Cancer Center, La Jolla
  • USC/Norris Comprehensive Cancer Center, Los Angeles
  • and 2 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT04752722

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.